| 2.05 -0.05 (-2.38%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.55  |
1-year : | 2.99 |
| Resists | First : | 2.18 |
Second : | 2.55 |
| Pivot price | 1.88 |
|||
| Supports | First : | 1.58 | Second : | 1.31 |
| MAs | MA(5) : | 1.69 |
MA(20) : | 1.9 |
| MA(100) : | 2.51 |
MA(250) : | 2.07 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 9.9 |
D(3) : | 8.4 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 3.81 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AADI ] has closed above bottom band by 11.6%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.68 - 1.69 | 1.69 - 1.7 |
| Low: | 1.56 - 1.57 | 1.57 - 1.58 |
| Close: | 1.62 - 1.64 | 1.64 - 1.65 |
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Sat, 22 Mar 2025
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Tue, 18 Mar 2025
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
Tue, 18 Mar 2025
Aadi Bioscience takes flight with new moniker: Whitehawk Therapeutics - Fierce Pharma
Mon, 17 Mar 2025
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update - BioSpace
Wed, 05 Mar 2025
Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
Tue, 04 Mar 2025
How Will Aadi Bioscience's $100M Cash Infusion Transform Its ADC Pipeline? - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 46 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 50 (%) |
| Shares Short | 794 (K) |
| Shares Short P.Month | 706 (K) |
| EPS | -2.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.79 |
| Profit Margin | -246.1 % |
| Operating Margin | -149.4 % |
| Return on Assets (ttm) | -35.3 % |
| Return on Equity (ttm) | -66 % |
| Qtrly Rev. Growth | 21 % |
| Gross Profit (p.s.) | -0.6 |
| Sales Per Share | 0.54 |
| EBITDA (p.s.) | -1.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -54 (M) |
| Levered Free Cash Flow | -36 (M) |
| PE Ratio | -0.71 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 3.06 |
| Price to Cash Flow | -1.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|